Jay Norman, president of Quintiles Consulting, discusses the changing landscape of drug development and suggests that better, evidence-based decisions, combined with smart sourcing strategies, will differentiate the future winners.

The pharmaceutical industry is at a transformational moment. The financial returns once realized will be tougher to realize; and for large pharma companies, there’s a series of questions over what the future growth strategy should be. With fewer FDA approvals, diminishing pipelines and the decaying blockbuster business model, the imperative to adopt new growth strategies is paramount.

Read more of this story.